Allergic sensitization and obstructive airway diseases among an adult rural population in Nepal
Nepalese Respiratory Journal · 2022
DOI: 10.3126/nrj.v1i1.45232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nepalese Respiratory Journal, 2022. Verfasst von Arne Drews und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
The relevance of the obstructive lung diseases asthma and COPD and IgE-mediated allergy in Nepal is still poorly characterized.
Method
In a cross-sectional study in rural Nepal 199 persons were characterized with a questionnaire, skin prick tests, spirometry and total IgE concentration in serum.
Results
About 20% of the women and 50% of the men were current smokers. Half of the study population used biomass fuel at home to cook or to heat and 70% of the study participants experienced dust-exposure at work or at home. 50% of the women and 30% of the men had a history of COPD, while 57% of the women and 53% of the men had symptoms of respiratory allergy. 18% of the women and 16% of the men used inhaler devices. 62% of the women and 66% of the men had a total IgE concentration in serum >100 IU/mL. About 30% of the women had a FEV1 < 80% and about 10 % had a FEV1 < 40%, also 30% of the men had a FEV1
Zitieren
APA
Drews, A., Lama, P., Nepal, N., Joshi, R. D., Gran, A., & Schreiber, J. (2022). Allergic sensitization and obstructive airway diseases among an adult rural population in Nepal. Nepalese Respiratory Journal. https://doi.org/10.3126/nrj.v1i1.45232
Vancouver
Drews A, Lama P, Nepal N, Joshi RD, Gran A, Schreiber J. Allergic sensitization and obstructive airway diseases among an adult rural population in Nepal. Nepalese Respiratory Journal. 2022. doi:10.3126/nrj.v1i1.45232
BibTeX
@article{Drews2022,
author = {Drews, Arne and Lama, Poonam and Nepal, Niraj and Joshi, Rajesh Dhoj and Gran, Anja and Schreiber, Jens},
title = {Allergic sensitization and obstructive airway diseases among an adult rural population in Nepal},
journal = {Nepalese Respiratory Journal},
year = {2022},
doi = {10.3126/nrj.v1i1.45232}
}
EUVIMED